Infliximab dose tailored to control Crohn’s inflammation
Treatments studied
Part of Digestive system clinical trials.
This trial tests a more precise way to start infliximab (a Crohn’s medicine) and adjust dosing based on how your body responds. It aims to better control Crohn’s inflammation early and keep it under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 6 to 22 (or your parent/guardian can consent if under 18)
- You were diagnosed with Crohn’s within the last 90 days
- You have not used anti-TNF medicines before (including infliximab)
- You have active Crohn’s symptoms and signs of intestinal inflammation from recent tests
- You must have a negative TB blood test and, if you menstruate, a negative pregnancy test
- You should not have ulcerative colitis or other non-Crohn inflammatory bowel diseases
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether people with Crohn’s disease or ulcerative colitis who are currently well-controlled can safely use less-frequent anti-TNF medicine. It may help reduce treatment intensity while keeping inflammation under control.
This trial studies a combination of immune-suppressing treatments for children with Crohn’s disease that is not well controlled. It may help reduce inflammation and improve symptoms if you meet the study’s disease-activity and safety requirements.
This study keeps track of how infliximab works and how safe it is in Chinese children with moderate-to-severe active Crohn’s disease. You may be eligible if this is the first time your child is starting infliximab and you agree to provide study information.
This study measures how infliximab (a medicine that calms immune inflammation) moves through the body in children with Crohn’s disease. It mainly helps doctors understand dosing and drug levels, especially when treatment is newly starting.
This study tests whether adjusting the dose of infliximab (a biologic medicine given by IV) based on drug levels in your blood works better for treating draining fistulas caused by Crohn's disease. It is for people who have not tried other biologics and whose fistulas have not healed with usual treatments.
This trial looks at whether a specific genetic marker (HLADQA1*05) is linked to how well infliximab works in adults with Crohn’s disease. It may help doctors better predict who benefits from infliximab in people with Crohn’s.
Hear when a new Crohn Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.